Mavoglurant

Mavoglurant

Mavoglurant (also known as AFQ056) is a drug that acts as a selective antagonist for the metabotropic glutamate receptor 5 (mGluR5). It has been investigated for its potential therapeutic effects in various neurological disorders and psychiatric conditions.

Mechanism of Action

Mavoglurant works by inhibiting the activity of mGluR5, a receptor that plays a crucial role in the modulation of glutamate, the primary excitatory neurotransmitter in the central nervous system. By blocking mGluR5, mavoglurant can potentially reduce excessive glutamate activity, which is implicated in several neurological and psychiatric disorders.

Therapeutic Uses

Mavoglurant has been studied for its potential use in treating conditions such as Fragile X syndrome, Parkinson's disease, and anxiety disorders.

Fragile X Syndrome

Fragile X syndrome is a genetic disorder that causes intellectual disability, behavioral and learning challenges, and various physical characteristics. Mavoglurant has been investigated as a treatment to alleviate some of the symptoms associated with this condition by modulating glutamate signaling.

Parkinson's Disease

In Parkinson's disease, mavoglurant has been explored for its potential to manage levodopa-induced dyskinesia, a common side effect of long-term levodopa therapy. By inhibiting mGluR5, mavoglurant may help reduce these involuntary movements.

Anxiety Disorders

Mavoglurant has also been studied for its anxiolytic effects, given the role of glutamate in anxiety and stress responses. By modulating mGluR5 activity, mavoglurant may offer a new approach to treating anxiety disorders.

Clinical Trials

Several clinical trials have been conducted to evaluate the efficacy and safety of mavoglurant in various conditions. While some studies have shown promising results, others have not demonstrated significant benefits, leading to ongoing research and development.

Side Effects

Common side effects of mavoglurant may include headache, dizziness, and nausea. As with any medication, the risk of side effects must be weighed against the potential therapeutic benefits.

See Also

• Metabotropic glutamate receptor
• Glutamate
• Fragile X syndrome
• Parkinson's disease
• Anxiety disorders

Related Pages

• Metabotropic glutamate receptor 5
• Glutamate receptor
• Neurological disorder
• Psychiatric condition